Keytruda and Chemotherapy could Revolutionise Treatment for Breast Cancer Patients

Pharmaceutical

Merck & Co's immunotherapy medication Keytruda has been proven to dramatically lower the risk of breast cancer recurrence when given at the proper time and in conjunction with chemotherapy. Keytruda is currently administered to treat a variety of cancers, assisting the immune system in the destruction of cancer cells.

The research revealed that combining immunotherapy and chemotherapy before getting tumour removal surgery had a good impact.

“combining immunotherapy and chemotherapy before getting tumour removal surgery had a good impact“

A group of women in stages 2 and 3 of TNBC (triple-negative breast cancer) were given Keytruda prior to surgery, with a secondary treatment following surgery. These women have a 37% reduced chance of the illness recurring than those treated solely treated with chemotherapy.

TNBC accounts for approximately 15% of breast cancers, with over 8,000 instances detected each year in the UK.

The study lead, Professor Peter Schmid explained that “we now have long-term results demonstrating that the combination therapy significantly reduces recurrences by approximately 37%, including reduction of secondary breast cancer by 39%. This means that the cure rate for these cancers is significantly increased. This new treatment may save as many as 10,000 lives per year.”

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.

See all the latest jobs in Pharmaceutical
Return to news